BPG is committed to discovery and dissemination of knowledge
Cited by in CrossRef
For: Jacobson I, Zeuzem S, Flisiak R, Knysz B, Lueth S, Zarebska-Michaluk D, Janczewska E, Ferenci P, Diago M, Zignego AL, Safadi R, Baruch Y, Abdurakhmanov D, Shafran S, Thabut D, Bruck R, Gadano A, Thompson AJ, Kopit J, McPhee F, Michener T, Hughes EA, Yin PD, Noviello S. Daclatasvir vs telaprevir plus peginterferon alfa/ribavirin for hepatitis C virus genotype 1. World J Gastroenterol 2016; 22(12): 3418-3431 [PMID: 27022224 DOI: 10.3748/wjg.v22.i12.3418]
URL: https://www.wjgnet.com/1007-9327/full/v22/i12/3418.htm
Number Citing Articles
1
Michael P. Manns, Benjamin Maasoumy. Breakthroughs in hepatitis C research: from discovery to cureNature Reviews Gastroenterology & Hepatology 2022; 19(8): 533 doi: 10.1038/s41575-022-00608-8
2
Xiaoqiong Duan, Xinzhong Liao, Shilin Li, Yujia Li, Min Xu, Yancui Wang, Haiyan Ye, Hang Zhao, Chunhui Yang, Xiang Zhu, Limin Chen. Transmembrane Protein 2 Inhibits Zika Virus Replication Through Activation of the Janus Kinase/Signal Transducers and Activators of Transcription Signaling PathwayFuture Virology 2019; 14(1): 9 doi: 10.2217/fvl-2018-0115
3
Dorota Zarębska-Michaluk, Michał Brzdęk, Jerzy Jaroszewicz, Magdalena Tudrujek-Zdunek, Beata Lorenc, Jakub Klapaczyński, Włodzimierz Mazur, Adam Kazek, Marek Sitko, Hanna Berak, Justyna Janocha-Litwin, Dorota Dybowska, Łukasz Supronowicz, Rafał Krygier, Jolanta Citko, Anna Piekarska, Robert Flisiak. Best therapy for the easiest to treat hepatitis C virus genotype 1b-infected patientsWorld Journal of Gastroenterology 2022; 28(45): 6380-6396 doi: 10.3748/wjg.v28.i45.6380
4
Dorota Zarębska-Michaluk, Robert Flisiak, Marta Flisiak-Jackiewicz. Management of hepatitis B and hepatitis C coinfection: an expert reviewExpert Review of Anti-infective Therapy 2020; 18(10): 1033 doi: 10.1080/14787210.2020.1776112
5
Michał Brzdęk, Krystyna Dobrowolska, Robert Flisiak, Dorota Zarębska-Michaluk. Genotype 4 hepatitis C virus-a review of a diverse genotypeAdvances in Medical Sciences 2023; 68(1): 54 doi: 10.1016/j.advms.2022.12.003
6
Dorota Zarębska-Michaluk, Jerzy Jaroszewicz, Anna Parfieniuk-Kowerda, Małgorzata Pawłowska, Ewa Janczewska, Hanna Berak, Justyna Janocha-Litwin, Jakub Klapaczyński, Krzysztof Tomasiewicz, Anna Piekarska, Rafał Krygier, Jolanta Citko, Olga Tronina, Krystyna Dobrowolska, Robert Flisiak. Pangenotypic and Genotype-Specific Antivirals in the Treatment of HCV Genotype 4 Infected Patients with HCV Monoinfection and HIV/HCV CoinfectionJournal of Clinical Medicine 2022; 11(2): 389 doi: 10.3390/jcm11020389
7
D T Abdurakhmanov, T P Rozina, E N Nikulkina, E Z Burnevich, E L Tanashuk, M V Severov, A L Filatova, S Yu Milovanova, V V Karpov, S V Moiseev. Antiviral therapy of chronic hepatitis C: 30 years success storyTerapevticheskii arkhiv 2019; 91(11): 110 doi: 10.26442/00403660.2019.11.000470
8
Dorota Zarębska-Michaluk, Robert Flisiak, Ewa Janczewska, Hanna Berak, Włodzimierz Mazur, Justyna Janocha-Litwin, Rafał Krygier, Beata Dobracka, Jerzy Jaroszewicz, Anna Parfieniuk-Kowerda, Krystyna Dobrowolska, Piotr Rzymski. Does a detectable HCV RNA at the end of DAA therapy herald treatment failure?Antiviral Research 2023; 220: 105742 doi: 10.1016/j.antiviral.2023.105742
9
Na Yang, Chaomin Sun, Lixin Zhang, Jianguo Liu, Fuhang Song. Identification and Analysis of Novel Inhibitors against NS3 Helicase and NS5B RNA-Dependent RNA Polymerase from Hepatitis C Virus 1b (Con1)Frontiers in Microbiology 2017; 8 doi: 10.3389/fmicb.2017.02153
10
Iandra Holzmann, Cristiane V. Tovo, Roseline Minmé, Mônica P. Leal, Michele P. Kliemann, Camila Ubirajara, Amanda A. Aquino, Bruna Araujo, Paulo R.L. Almeida. Effectiveness of chronic hepatitis C treatment with direct-acting antivirals in the Public Health System in BrazilThe Brazilian Journal of Infectious Diseases 2018; 22(4): 317 doi: 10.1016/j.bjid.2018.06.004
11
Seyed Moayed Alavian, Mohammad Saeid Rezaee-Zavareh. Daclatasvir-based Treatment Regimens for Hepatitis C Virus Infection: A Systematic Review and Meta-AnalysisHepatitis Monthly 2016; 16(9) doi: 10.5812/hepatmon.41077
12
K. Rajender Reddy, Stanislas Pol, Paul J. Thuluvath, Hiromitsu Kumada, Joji Toyota, Kazuaki Chayama, James Levin, Eric J. Lawitz, Adrian Gadano, Wayne Ghesquiere, Guido Gerken, Maurizia R. Brunetto, Cheng‐Yuan Peng, Marcelo Silva, Simone I. Strasser, Jeong Heo, Fiona McPhee, Zhaohui Liu, Rong Yang, Misti Linaberry, Stephanie Noviello. Long‐term follow‐up of clinical trial patients treated for chronic HCV infection with daclatasvir‐based regimensLiver International 2018; 38(5): 821 doi: 10.1111/liv.13596
13
Michał Brzdęk, Dorota Zarębska-Michaluk, Federica Invernizzi, Marta Cilla, Krystyna Dobrowolska, Robert Flisiak. Decade of optimizing therapy with direct-acting antiviral drugs and the changing profile of patients with chronic hepatitis CWorld Journal of Gastroenterology 2023; 29(6): 949-966 doi: 10.3748/wjg.v29.i6.949
14
Paweł Pabjan, Michał Brzdęk, Magdalena Chrapek, Kacper Dziedzic, Krystyna Dobrowolska, Katarzyna Paluch, Anna Garbat, Piotr Błoniarczyk, Katarzyna Reczko, Piotr Stępień, Dorota Zarębska-Michaluk. Are There Still Difficult-to-Treat Patients with Chronic Hepatitis C in the Era of Direct-Acting Antivirals?Viruses 2022; 14(1): 96 doi: 10.3390/v14010096
15
Xiaobo Zhu, Mingqi Wang, Mei Liu, Xinghao Yu, Peng Huang. Efficacy and Safety of Direct-Acting Antivirals for Treatment-Naive Patients with Genotype 1 Hepatitis C Virus InfectionPersonalized Medicine 2019; 16(5): 421 doi: 10.2217/pme-2018-0121